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Abstract 
Background: PCSK9 inhibition is a new powerful cholesterol‑lowering strategy. Recently, it was reported that CETP 
inhibitors influence PCSK9 levels as an off‑target effect. We explored the relationship between circulating PCSK9 levels 
and CETP activity in patients with metabolic disease who were not on lipid‑lowering therapy.
Methods: Plasma CETP activity and PCSK9 levels were measured in 450 participants (median age, 58 years; 49 % 
women) who attended the metabolism unit because of metabolic syndrome (MetS) (78 %), atherogenic dyslipidemia 
(32 %), obesity (50 %), type 2 diabetes mellitus (72 %), and other risk factors (13 %). A 6 week lipid‑lowering drug 
wash‑out period was established in treated patients.
Results: Both PCSK9 levels and CETP activity were higher in patients with an increasing number of MetS compo‑
nents. PCSK9 levels were positively correlated with CETP activity in the entire cohort (r = 0.256, P < 0.0001) independ‑
ent of age, gender, body mass index (BMI), systolic blood pressure (SBP), LDL cholesterol (LDL‑C), triglycerides and 
glucose. Individuals with the loss‑of‑function PCSK9 genetic variant rs11591147 (R46L) had lower levels of PCSK9 
(36.5 %, P < 0.0001) and LDL‑C (17.8 %, P = 0.010) as well as lower CETP activity (10.31 %, P = 0.009). This association 
remained significant in the multiple regression analysis even after adjusting for gender, age, BMI, LDL‑C, triglycerides, 
glucose, lecithin‑cholesterol acyltransferase, SBP and MetS (P = 0.003).
Conclusions: Our data suggest a metabolic association between PCSK9 and CETP independent of lipid‑lowering 
treatment. The clinical implications of this metabolic relationship could be relevant for explaining the effect of PCSK9 
and CETP inhibition on overall lipid profiles.
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Background
High levels of LDL cholesterol (LDL-C) and triglycerides 
and low levels of HDL cholesterol (HDL-C) are associ-
ated with an increased risk of cardiovascular events. 
Over the past few decades, mortality related to cardio-
vascular disease has steadily decreased in western coun-
tries; however, in recent years, the decline has been offset 
by the increase in obesity. Obesity is strongly associated 
with metabolic syndrome and the atherogenic dyslipi-
demia resulting from insulin resistance. While lifestyle 
treatments are effective, drugs targeting individual risk 
factors are often required. Novel approaches are directed 
towards the treatment of several risk factors with one 
drug. Despite the significant improvements many 
patients obtain with statins, residual risk remains for 
those who cannot achieve optimal levels of LDL-C or for 
those who are statin intolerant, underscoring the need 
for additional therapies to further manage this risk [1–3]. 
Inhibitors of proprotein convertase subtilisin/kexin 9 
(PCSK9) and cholesteryl ester transfer protein (CETP) 
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are both under current investigation as potential drugs 
for reducing cardiovascular disease [4, 5].
PCSK9 is mainly produced in the liver and intestine 
and is secreted into the circulation, where it mediates 
LDL receptor (LDLR) degradation in lysosomes, result-
ing in fewer LDLRs on the cell membrane [6]. There-
fore, PCSK9 decreases LDL-C clearance from circulation 
and elevates plasma LDL-C. PCSK9 inhibitors increase 
cell surface LDLR expression and reduce LDL-C levels 
by more than 60  % [7]. Gain-of-function mutations in 
PCSK9 decrease the number of LDLRs on the cell sur-
face and represent a rare cause of familial hypercholes-
terolemia [8], while loss-of-function (LOF) mutations in 
PCSK9 result in an increased number of LDLRs on the 
cell surface, leading to a lifelong low levels of LDL-C and 
a markedly reduced cardiovascular risk [9, 10].
CETP mediates the transport of cholesteryl ester from 
HDL to apolipoprotein B-containing lipoproteins such 
as VLDL and LDL. Animal studies, as well as clinical and 
epidemiologic evidence, have suggested that inhibiting 
CETP is an effective strategy for raising HDL-C levels 
and reducing LDL-C levels. Inhibiting CETP decreases 
the concentration of LDL-C by up to 45 % and increases 
the concentration of HDL-C by up to 180 % [11–14].
Recently, it has been reported that CETP inhibitors 
influence PCSK9 levels as an off-target effect [15–17]. 
Furthermore, some PCSK9 antibodies reduce the expres-
sion of SREBP-regulated genes [18]. The PCSK9 and 
CETP genes are regulated by members of the SREBP 
transcription factor family [19, 20]. In  vitro data have 
shown that CETP inhibitors decrease the occupancy of 
SREBP1 and SREBP2 on the sterol regulatory element 
within the PCSK9 promoter [21, 22]. Taken together, 
there is considerable interest in the relationship between 
CETP and PCSK9 in humans. Therefore, a treatment-
independent metabolic relationship between these mol-
ecules cannot be ruled out.
Accordingly, the current study was conducted to exam-
ine the relationship between plasma CETP activity and 
PCSK9 levels in patients with metabolic disturbances. 
In addition, we studied the impact of the LOF PCSK9 
genetic variant rs11591147 (R46L).
Methods
Subjects
We studied 450 participants (median age, 60 years; 49 % 
women) who attended the metabolism unit because 
of metabolic syndrome (MetS; 78  %) according to the 
ATPIII criteria, atherogenic dyslipidemia (AD; 32  %), 
obesity (defined as BMI ≥ 30 kg/m2; 50 %), type 2 diabe-
tes mellitus (T2DM; 72 %), or other risk factors (hyper-
cholesterolemirefa/hypertriglyceridemia; 13 %). Subjects 
with chronic lung, renal or liver disease; cancer; or any 
other serious disease were excluded. Patients on lipid-
lowering drugs (N = 391) underwent a wash-out period 
of at least 6  weeks (8  weeks if they were on fibrates). 
Anamnesis and physical examination data were recorded. 
The Hospital Ethical Committee approved this study, and 
all the patients provided written consent to participate in 
the study.
Blood sample collection and storage
A blood sample was obtained after overnight fasting from 
each patient in the study cohort. Plasma and serum ali-
quots were prepared and stored at −80 °C in the BioBanc 
at our centre until further use. Cellular buffy coats were 
obtained from 425 individuals, and the cells were stored 
at −80 °C until DNA analyses were performed.
PCSK9, CETP activity and biochemical analysis
Biochemical parameters, lipids, and apolipoproteins were 
measured using colorimetric, enzymatic and immuno-
turbidimetric assays (Spinreact, SA, Spain; Wako Chemi-
cals GmbH, Germany; Polymedco, NY, US; CV  < 4  %) 
that were adapted to a Cobas Mira Plus Autoanalyser 
(Roche Diagnostics, Spain). The lipid profile was analysed 
according to Spintrol “H” CAL (Spinreact, SA, Spain) 
GC–MS reference methods. Spintrol “H” Normal (Spin-
react, SA, Spain) was used as a quality control. All sam-
ples were subjected to the Liposcale test. This advanced 
lipoprotein test is based on 2D diffusion-ordered (1)H 
nuclear magnetic resonance (NMR) spectroscopy. This 
method adds diffusion coefficients to classical NMR 
determinations to provide a direct measure of mean 
particle size and number [23]. CETP activity was meas-
ured using a fluorometric assay (BioVision, CA, USA). 
Lecithin-cholesterol acyltransferase (LCAT) activity was 
assessed using a fluorometric assay (Calbiochem, CA, 
USA). Circulating PCSK9 levels were measured using 
commercial ELISA kits (R&D Systems, MN, USA).
SNP selection and genotyping
We genotyped the rs11591147 (R46L) genetic variant of 
PCSK9, which was selected from the International Hap-
Map database (http://hapmap.ncbi.nlm.nih.gov/). The 
LOF PCSK9 genetic variant rs11591147 (R46L) is asso-
ciated with lower levels of plasma PCSK9 [24]. Genomic 
DNA was extracted from peripheral leukocytes that had 
been isolated from anticoagulated venous blood using 
a QIAamp DNA Blood Kit (Qiagen Iberia SL, Madrid, 
Spain) according to the manufacturer’s instructions. 
The DNA was genotyped for the genetic variant on the 
Sequenom MassARRAY platform using the iPLEX Gold 
protocol as specified by the manufacturer (Sequenom 
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Inc., San Diego, CA) [25]. The genotypes of 5 of the sam-
ples were confirmed using duplicate Sequenom runs, and 
they showed 100  % consistency. Genotyping was per-
formed at the Spanish National Genotyping Centre.
Statistical analysis
The results are expressed as the mean  ±  SD for nor-
mally distributed data, the median (interquartile range) 
for data that was not normally distributed, and frequen-
cies for categorical data. The differences between groups 
were assessed using the Mann–Whitney U test or the 
Kruskal–Wallis test. Correlations were evaluated using 
Spearman’s test. Multiple linear regression analysis was 
used to test the association between CETP activity and 
PCSK9 levels with the following covariates: age, gender, 
BMI, systolic blood pressure (SBP), LDL-C, triglycerides, 
glucose, LCAT and MetS. All the association analyses 
were adjusted for age, sex and BMI (when appropriate). 
The Hardy–Weinberg equilibrium test was performed in 
the studied population using a χ2 test. Statistical analyses 
were performed using SPSS software (IBM SPSS Statis-
tics, version 22.0). All statistical tests were two-tailed and 
P < 0.05 was taken as significant.
Results
Participant characteristics and biochemical parameters
The clinical, metabolic and biochemical parameters of the 
450 recruited subjects (male/female: 231/219) are shown 
in Table 1. The median age of the study participants was 
60 years; 78 % had MetS, 32 % had AD, 50 % had obesity, 
72 % had T2DM, and 13 % had other risk factors.
Both PCSK9 levels and CETP activity were significantly 
elevated in patients with MetS [327.9 (261.9–417.9) vs 
288.1 (233.7–360.9) ng/mL, P < 0.004, and 12.03 (10.33-
14.15) vs 10.90 (10.08–12.02) nmol/L per h, P < 0.0001, 
respectively]. PCSK9 levels and CETP activity increased 
significantly as the number of MetS components 
increased (P = 0.002 and P < 0.0001, respectively) (Fig. 1). 
After adjustment PCSK9 levels and CETP activity for age 
and gender, the association with the MetS components 
remained significant in both parameters (P < 0.0001).
Associations between CETP activity and PCSK9 levels
CETP activity stratified by quartiles of PCSK9 concen-
tration in the whole cohort is shown in Fig. 2. A higher 
PCSK9 quartile corresponded with higher CETP activ-
ity (P  <  0.001). The univariate analysis showed that this 
relation persisted after adjustment for age, gender, BMI, 
SBP, triglycerides, LDL-C and glucose (P = 0.003). A sig-
nificant positive association between PCSK9 and CETP 
was observed in the whole group (r = 0.256, P < 0.001) 
(Table  2). After adjusting PCSK9 levels for age, gen-
der, BMI, SBP, LDL-C, triglycerides and glucose, the 
correlation with CETP remained significant (r  =  0.158, 
P = 0.003). CETP was also significantly positively associ-
ated with SBP, diastolic blood pressure, cholesterol, LDL-
C, triglycerides and glucose and negatively associated 
Table 1 Characteristics of the study subjects
The data are presented as the mean ± SD for normally distributed data, the 
median (IQR) for non-normally distributed data or as the percentage for 
categorical variables
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, 
AD atherogenic dyslipidemia, MetS metabolic syndrome, T2DM type 2 diabetes 
mellitus, LDL-C LDL cholesterol, HDL-C HDL cholesterol
a SNP analysis was performed in 425 individuals
Variable N = 450
Age (years) 60 (50–66)
Gender (% men) 51.3
BMI (Kg/m2) 30.0 (26.9–35.0)
SBP(mmHg) 135 (125–149)





Cholesterol (mmol/L) 5.20 (4.54–6.19)
Triglycerides (mmol/L) 1.54 (0.99–2.45)
LDL‑C (mmol/L) 3.27 (2.55–4.07)
HDL‑C (mmol/L) 1.40 (1.21–1.62)
Glucose (mg/dL) 128.5 (101.3–164.9)
Apo B100 (mg/dL) 101.0 (84.0–120.0)
Apo A1 (mg/dL) 137.9 ± 14.9
CETP activity (nmol/L per h) 11.6 (10.2–13.3)
LCAT activity (470/390 nm) 2.14 (2.07–2.24)
PCSK9 (ng/mL) 319.9 (254.4–403.9)
PCSK9 rs11591147 GG 94.8
Genotypea, (%) GT 5.2
Lp particle number
 VLDL (nmol/L) 49.7 (28.5–97.8)
  Large VLDL (nmol/L) 1.83 (1.01–2.99)
  Medium VLDL (nmol/L) 7.87 (4.52–13.6)
  Small VLDL (nmol/L) 39.9 (22.7–82.2)
 LDL (nmol/L) 892.3 (681.8–1175.8)
  Large LDL (nmol/L) 113.4 (87.0–149.4)
  Medium LDL (nmol/L) 319.4 (234.3–417.2)
  Small LDL (nmol/L) 463.5 (337.9–618.5)
 HDL (µL/L) 25.3 (21.6–29.4)
  Large HDL (µL/L) 0.15 (0.11–0.19)
  Medium HDL (µL/L) 6.94 (5.08–9.21)
  Small HDL (µL/L) 17.9 (15.5–20.9)
Lp size (diameter, nm)
 VLDL 42.6 ± 0.57
 LDL 21.0 (20.9–21.1)
 HDL 8.19 (8.12–8.24)
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with LCAT (P  <  0.05) in the whole group. LDL particle 
number showed a positive association with CETP activ-
ity (P < 0.001), whereas there was a negative association 
with medium HDL particles (r = −0.193, P < 0.001) and 
positive associations with small and large HDL particles 
(P  <  0.001). PCSK9 was positively associated with LDL 
and LDL particle number and inversely associated with 
LDL size. PCSK9 levels also correlated with an AD profile 
(Table 2).
To further explore the relationship between CETP 
and PCSK9, a linear regression model was generated 
(Table  3). The significant direct relation between CETP 
and PCSK9 remained robust after additional adjustment 
for the following covariates (model 5): age, gender, BMI, 
SBP, LDL-C, triglycerides, glucose, LCAT and MetS (beta 
0.110; P = 0.003).
Fig. 1 PCSK9 levels and CETP activity according to the number of 
MetS components (0 8.5 %; 1 6.9 %; 2 8.2 %; 3 18.7 %; 4 32.7 %; 5 
25.0 %). The data are presented as the mean ± SEM. P values were 
obtained using the Kruskal–Wallis test. PCSK9: P = 0.002; CETP: 
P < 0.0001. The univariate analysis showed that this relation persisted 
after adjustment for age, gender in both parameters (P < 0.0001)
Fig. 2 CETP activity across PCSK9 quartiles. CETP activity are 
presented as the mean ± SEM. P values were obtained using the 
Kruskal–Wallis test. Quartile 1 (median (IQR) (218.7 (191.2–232.6); 
N = 112), Quartile 2 (283.2 (269.5–299.8); N = 113), Quartile 3 (356.7 
(341.2–377.8); N = 113) and Quartile 4 (471.9 (435.2–531.4; N = 112). 
The univariate analysis showed that this relation persisted after 
adjustment for age, gender, BMI, SBP, triglycerides, LDL‑C and glucose 
(P = 0.003)
Table 2 Spearman’s correlations of CETP activity and PCSK9 
levels with clinical and metabolic variables
a After adjusting PCSK9 for age, gender, BMI, SBP, LDL-C, triglycerides and 
glucose, the Spearman’s correlation with CETP remained significant (r = 0.158, 
P = 0.003)
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, 
LDL-C LDL cholesterol, HDL-C HDL cholesterol
CETP PCSK9
r P r P
CETP 1.000 – 0.256a <0.0001
PCSK9 0.256a <0.0001 1.000 –
Age −0.088 0.063 0.045 0.346
BMI 0.020 0.679 0.052 0.268
SBP 0.208 <0.0001 0.123 0.022
DBP 0.129 0.016 0.085 0.112
Cholesterol 0.585 <0.0001 0.194 <0.0001
Triglycerides 0.491 <0.0001 0.210 <0.0001
LDL‑C 0.412 <0.0001 0.179 <0.0001
HDL‑C 0.134 0.004 0.109 0.021
ApoB100 0.494 <0.0001 0.194 <0.0001
ApoA1 −0.002 0.970 0.135 0.004
Glucose 0.186 <0.0001 0.215 <0.0001
LCAT −0.251 <0.0001 −0.072 0.127
Lp particles number
 Total VLDL 0.419 <0.0001 0.176 <0.0001
 Large VLDL 0.411 <0.0001 0.160 0.001
 Medium VLDL 0.413 <0.0001 0.172 <0.0001
 Small VLDL 0.420 <0.000 0.177 <0.0001
 Total LDL 0.300 <0.0001 0.134 0.004
 Large LDL 0.246 <0.0001 0.093 0.049
 Medium LDL 0.234 <0.0001 0.111 0.019
 Small LDL 0.332 <0.0001 0.152 0.001
 Total HDL 0.098 0.038 0.024 0.614
 Large HDL 0.109 0.021 0.043 0.359
 Medium HDL −0.193 <0.0001 −0.044 0.356
 Small HDL 0.241 <0.0001 0.071 0.136
Lp size
 VLDL −0.276 <0.0001 −0.114 0.015
 LDL −0.200 <0.0001 −0.107 0.023
 HDL −0.362 <0.0001 −0.104 0.027
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Association of rs11591147 PCSK9 genetic variant 
with CETP activity, PCSK9 and LDL‑C concentrations
The impact of the LOF PCSK9 genetic variant rs11591147 
(R46L) on CETP activity was studied in 425 patients. The 
frequency of PCSK9 rs11591147 (R46L) heterozygosity 
was 5.2 % among the whole group (Table 1). As expected, 
individuals harbouring the variant GT genotype had sig-
nificant lower levels of LDL-C [2.55 (2.40–3.46) mmol/L 
vs 3.28 (2.55–4.08), P = 0.010] and PCSK9 [193.6 (147.8–
264.9) vs 328.8 (258.9–410.2) ng/mL, P  <  0.0001)] than 
individuals with the wild type GG genotype (Fig.  3a, b, 
respectively). Interestingly, individuals with the variant 
GT genotype had significantly lower CETP activity than 
individuals with the wild type GG genotype [10.15 (9.59–
11.93) vs 11.65 (10.31–13.50) nmol/L per h, P = 0.009]; 
this finding remained significant (P = 0.044) after adjust-
ing for age, gender and BMI (Fig. 3c).
Discussion
PCSK9 plasma concentrations and CETP activity are 
directly correlated
In this study, we explored the association between circu-
lating PCSK9 concentration and plasma CETP activity in 
a group of patients with increased cardiovascular risk due 
to metabolic alterations who were not on lipid-lowering 
therapies or who underwent a wash-out period. We found 
a moderate but significant and robust direct association 
between both parameters that was maintained after mul-
tiple adjustment for confounding covariates, including 
plasma lipid concentrations. This is the first report sug-
gesting a direct correlation between these two biochemi-
cal parameters in humans. Moreover, our data suggest that 
this association is independent of intermediate factors.
Because both parameters had parallel behaviour in 
the presence of metabolic alterations, such as MetS 
components, a possible explanation could be that higher 
PCSK9 concentrations, which evoke higher LDL-C 
plasma levels, would increase CETP activity by increasing 
substrate concentration. Conversely, higher CETP activ-
ity would elicit higher LDL-C and PCSK9 concentrations. 
Abifadel et  al. observed that endogenous plasma CETP 
activity was significantly increased in familial hypercho-
lesterolemia patients carrying the PCSK9 Leu181Arg 
gain-of-function mutation. They suggest this effect could 
be due to an increase of plasma levels of cholesterol ester 
acceptors [26]. However, the association between PCSK9 
Table 3 Association between CETP activity and PCSK9 lev-
els
Linear regression analysis results are displayed as beta coefficients with the P 
and R2 values for each model. CETP was the dependent variable
BMI body mass index, LDL-C LDL cholesterol, TG triglycerides, Glu glucose, SBP 





 Model 1: crude (no adjustment) 0.253 <0.0001 0.064
 Model 2: age, gender and BMI 0.268 <0.0001 0.085
 Model 3: model 2 + LDL‑C, TG, and Glu 0.107 0.001 0.582
 Model 4: model 3 + SBP and LCAT 0.107 0.004 0.624
 Model 5: model 4 + MetS 0.110 0.003 0.624
Fig. 3 LDL‑C levels (a), PCSK9 (b) levels and CETP (c) activity accord‑
ing to rs11591147 PCSK9 variant. The data are presented as the 
mean ± SEM. There were 403 individuals with the wild type GG geno‑
type and 22 with the variant GT genotype. P values were obtained 
with the Mann–Whitney test
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and CETP activity in our study was maintained after 
adjusting for multiple covariates, including LDL-C plasma 
concentration, thereby weakening this hypothesis.
PCSK9 and CETP share molecular regulatory mechanisms
Recently, it was reported that CETP inhibitors influence 
PCSK9 levels as an off-target effect. In vivo data showed 
that CETP inhibitors decrease PCSK9 levels in humans 
[17] and in rhesus macaques [16]. This effect could 
explain why CETP inhibitors reduce (V)LDL-C. Dong 
et  al. demonstrated in liver cells that CETP inhibitors 
reduced the mature form of SREBP2, leading to attenu-
ated transcription of LDLR and its degrader PCSK9 [22]. 
In addition, Miyosawa et al. demonstrated that K-312, a 
new CETP inhibitor, decreased the occupancy of SREBP1 
and SREBP2 on the sterol regulatory element within the 
PCSK9 promoter [21]. Consistent with these results, 
van der Tuin et al. demonstrated in ApoE*-Leiden.CETP 
mice that anacetrapib lowers hepatic PCSK9 expression 
by interacting with SREBP2, leading to reduced plasma 
PCSK9 levels and increased hepatic LDLR increasing 
LDLR-mediated hepatic clearance of remnant lipopro-
tein and decreasing atherogenicity in animal models 
[15]. Although these studies suggest an effect of CETP 
inhibitors on PCSK9 independent of CETP itself, a meta-
bolic association between these parameters cannot be 
excluded. As in the PCSK9 gene, the promoter region 
of the CETP gene has recognition domains for SREBP1a 
and SREBP2, and thus a pathophysiological parallel regu-
latory mechanism that affects both PCSK9 and CETP 
protein expression must be considered. In our study, we 
did not measure CETP mass; however, CETP mass and 
ex vivo activity were highly correlated in previous stud-
ies [27]. To confirm this finding, we analysed CETP mass 
and activity in a group of 30 patients with T2DM. There 
was a significant positive association between CETP 
mass and activity (r =  0.543, P =  0.002) in the diabetic 
patient group (Additional file  1: Figure S1A). In addi-
tion, PCSK9 was also significantly positively associated 
with CETP mass (r = 0.521, P = 0.003) (Additional file 1: 
Figure S1B), supporting the hypothesis of common gene 
upregulation in patients with metabolic alterations.
In our cohort, 5.2  % of the patients harboured the 
PCSK9 R46L LOF mutation, similar to previous data in 
Caucasian subjects [24, 28]. This subgroup of patients 
had both low PCSK9 and LDL levels, and interestingly, 
CETP activity was also reduced. These data support 
the hypothesis that the correlation between PCSK9 and 
CETP activity is not dependent on external environ-
mental factors that influence these parameters. A pos-
sible mechanism could be that PCSK9 LOF mutations 
result in increased LDLR occupancy at the cell surface, 
thereby increasing LDL internalization and intracellular 
cholesterol concentrations and leading to lower SREBP 
activity, which could influence PCSK9, and possibly 
CETP, expression.
PCSK9 and CETP correlation could explained 
therapy‑induced global lipoprotein profile variations
There are several implications of this putative metabolic 
association that should be considered when ascertain-
ing the impact of CETP inhibitors on PCSK9 levels that 
is attributed to off-target effects. PCSK9 inhibitors, in 
addition to their important LDL-lowering effect, induce 
a moderate but consistent increase in HDL cholesterol 
concentration. Our data could partially explain this phe-
nomenon as a consequence of the decrease in CETP 
activity associated with lower PCSK9 levels.
In general, a parallel reduction of CETP activity along 
to lower PCSK9 levels could be seen as beneficial, how-
ever the overall effect of CETP on atherogenesis is under 
debate. While hypertriglyceridemia stimulates CETP 
enzymatic activity [29], a reduction on cholesterol ester 
transfer from triglyceride rich lipoprotein to HDL has 
been associated to coronary heart disease presence in 
diabetic patients [30]. If these observations are repro-
duced in patients on PCSK9 inhibitors treatment is not 
known, but it could explained the wide impact of these 
drugs on lipid profile affecting in a moderate way, triglyc-
erides and HDL reinforcing the role of this treatment in 
patients with combined hyperlipidemias.
Our study has several limitations. It was an observa-
tional study, and thus, we cannot explain the mechanisms 
underlying the findings. Unfortunately, we had no access 
to patients on PCSK9 inhibitors who could have provided 
more information regarding the CETP-PCSK9 associa-
tion; however, we have data on patients with genetically 
driven low PCSK9 levels. Our included patients with 
metabolic alterations, so we cannot extrapolate our find-
ings to other populations.
Conclusions
In conclusion, we report that PCSK9 plasma concentra-
tion is directly correlated with CETP activity in patients 
with metabolic imbalances. The mechanism underlying 
this association is not yet known, but it could explain the 
broad impact of drugs that regulate these two proteins on 
lipoprotein profiles.
Additional file
Additional file 1: Figure S1. Correlations between CETP activity and 
CETP mass (A) and between PCSK9 and CETP mass (B) in patients with 
T2DM (n=30). CETP mass was measured in human serum using a quanti‑
tative enzyme‑linked immunosorbent assay (ELISA) (American Diagnos‑
tica Gmbh). Spearman coefficients and P values are shown.
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